ABOUT US-BioRay

2020 官网升级中！现在您访问官网的浏览器设备分辨率宽度低于1280px
请使用高分辨率宽度访问。

ABOUT US

BioRay is a commercial-stage biopharmaceutical company aiming to transform the future of treatment for immune-mediated diseases and cancer

Scrllo Down

HOME COMPANY

BioRay Pharmaceutical Co., Ltd.

BioRay is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases. Its extensive autoimmune and oncology portfolio includes six marketed products and over 10 clinical-stage drug candidates. Operating a fully integrated platform with end-to-end capabilities across drug discovery, clinical development, manufacturing, and commercialization, BioRay has over 1,800 employees globally, with main sites in Taizhou, Hangzhou, Shanghai, and San Diego.

years

In Biologics R&D
+

Staff
+

Clinical Programs
L+

Manufacturing Capacity
Marketed Products

Discovery & Research

Deep expertise in antibody biology supported by multiple platforms in developing biosimilar, new mAb, ADC, bi-/tri-specific antibodies

Clinical Development

In-house clinical operation and regulatory teams with a proven track record for both biosimilar and new mAb approvals in China

Manufacturing

Strong CMC capabilities to support the entire R&D life-cycle; commercial-scale manufacturing capacity of 20,000L+

Commercialization

Six marketed products with an established commercial team since 2015; one of the top players in the auto-immune area in China

Our Values

Mission

To make a meaningful impact on people’s lives
Vision

To build a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery
Focus

To deliver life-changing treatments for patients living with immune-mediated diseases and cancer

Our History

KEY EVENTS

1956

Hisun Pharma established in Taizhou, China and still is one of the leading comprehensive pharmaceutical group in China

2003

Entered biologics R&D

2010

Expanded R&D and set up commercial scale manufacture facilities in Fuyang, Hangzhou

2015

1st product approved in China AnBaiNuo ® (bio-better etanercept) Commercial team established from Pfizer-Hisun joint-venture

2019

BioRay was established
PAG acquired a 58% stake of BioRay for RMB3.8B, becoming the largest private equity investment in China’s biotechnology industry to date
Anjianning® was launched

2020

BioRay(USA) was established
Provincial post-doctoral research workstation was established Anbainuo® pre-filled syringe was approved for clinical trial

2021

PAG, Hisun and Pinzhan increased their capital by RMB500M BR102 was entitled as key research and development program of Zhejiang province
Anbaite® (Infliximab for injection) was launched
The world's first anti-CD3 / CD19 / CD20 clinical application in China was approved

2022

BR105 injection completed first subject administration
Approved as a national postdoctoral research workstation obtained strategic financing of over 1.5 billion yuan from multiple institutions

2023

Application for market approval of Anbaixin® Tocilizumab injection accepted Anruize® injection of Trastuzumab approved for market launch
Anruixi® Zuberitamab Injection granted market approval
Clinical trial application for BR201 injection approved
Phase I clinical trial first dosing completed for Type I new drug BR108 injection
Clinical trial application for BR105 injection approved by the FDA
Zuberitamab Injection Anruixi® successfully included in the catalog of medicines covered by national medical insurance system

Our Team

At BioRay, we seek to deliver innovative, cost-effective and life-changing drugs for patients. We know what it takes to be great at BioRay and we are as passionate about our people as we are about our mission.

JOIN US

TO TOP